Knight Therapeutics (OTCMKTS:KHTRF) Stock Price Up 1.4% – Still a Buy?

Knight Therapeutics Inc. (OTCMKTS:KHTRF)’s stock price shot up 1.4% on Wednesday . The company traded as high as $4.43 and last traded at $4.23. 1,400 shares were traded during trading, a decline of 24% from the average session volume of 1,840 shares. The stock had previously closed at $4.18.

Analyst Ratings Changes

Separately, Mackie upgraded shares of Knight Therapeutics to a “buy” rating in a report on Tuesday, March 11th.

Knight Therapeutics Price Performance

The firm’s 50 day simple moving average is $3.98 and its 200-day simple moving average is $3.97.

About Knight Therapeutics

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.